Tonix Pharmaceuticals to Report Second-Quarter 2026 Financial Results on Aug. 10

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced it will report financial results and operational highlights for the second quarter of 2026 before hosting a conference call and webcast at 8:30 a.m. ET on Aug. 10, 2026. The announcement provides investors with an opportunity to assess the company’s performance and strategic direction, particularly following the recent approval of its flagship medicine, TONMYA, for fibromyalgia. A replay of the webcast will be available in the Investors section of the company’s website following the event. The full press release can be accessed at https://ibn.fm/A9CfR.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. This milestone underscores Tonix’s ability to bring innovative therapies to market and addresses a significant gap in pain management. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra.

Beyond its commercial success, Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. These trials could expand the drug’s indications and address large patient populations with limited treatment options. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. This program highlights Tonix’s commitment to addressing conditions with few approved therapies.

Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs target significant unmet needs in infectious disease and transplant medicine, potentially offering new preventive and therapeutic options. The company’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Investors can find the latest news and updates relating to TNXP in the company’s newsroom at https://ibn.fm/TNXP. The upcoming earnings call will provide further insights into Tonix’s financial health and operational progress, including updates on TONMYA’s commercial launch and pipeline advancements. As a commercial-stage company with a diversified portfolio, Tonix is positioned to capitalize on its recent successes while continuing to innovate in CNS and immunology.